Pharmacogenomics in practice: A case report of personalized inpatient psychiatric care

Alok Madan, Cory R. Walker, Benjamin Weinstein, James Chris Fowler

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Given variable response to psychotropic intervention, this case highlights the potential of pharmacogenomics to inform medical decision-making in a male with atypical psychosis and depression with longer-standing attentional difficulties. Likely because of his specific COMT polymorphism and intermediate metabolizing liver enzymes, when the patient's stimulant medications were titrated to affect for attentional needs, he became psychotic secondary to a hyperdopaminergic state. Past prescriptions of dopaminergic antidepressant agents (e.g., bupropion) likely would have exacerbated further the problem. The patient's serotonin transporter polymorphism also potentially was associated with SSRI inefficacy and increased side effects. Knowledge of the patient's genetically influenced departure from average response allowed for personalization of pharmacology with clinical improvement across measures of functioning.

Original languageEnglish (US)
Pages (from-to)433-439
Number of pages7
Issue number5
StatePublished - Apr 1 2015


  • Inpatient psychiatry
  • Pharmacogenomics
  • Psychosis
  • Psychotropic medications

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology


Dive into the research topics of 'Pharmacogenomics in practice: A case report of personalized inpatient psychiatric care'. Together they form a unique fingerprint.

Cite this